title: Cell division cycle 20 overexpression predicts poor prognosis for patients with lung adenocarcinoma.
abstract: The cell division cycle 20, a key component of spindle assembly checkpoint, is an essential activator of the anaphase-promoting complex. Aberrant expression of cell division cycle 20 has been detected in various human cancers. However, its clinical significance has never been deeply investigated in non-small-cell lung cancer. By analyzing The Cancer Genome Atlas database and using some certain online databases, we validated overexpression of cell division cycle 20 in both messenger RNA and protein levels, explored its clinical significance, and evaluated the prognostic role of cell division cycle 20 in non-small-cell lung cancer. Cell division cycle 20 expression was significantly correlated with sex (p = 0.003), histological classification (p < 0.0001), and tumor size (p = 0.0116) in non-small-cell lung cancer patients. In lung adenocarcinoma patients, overexpression of cell division cycle 20 was significantly associated with bigger primary tumor size (p = 0.0023), higher MKI67 level (r = 0.7618, p < 0.0001), higher DNA ploidy level (p < 0.0001), and poor prognosis (hazard ratio = 2.39, confidence interval: 1.87-3.05, p < 0.0001). However, in lung squamous cell carcinoma patients, no significant association of cell division cycle 20 expression was observed with any clinical parameter or prognosis. Overexpression of cell division cycle 20 is associated with poor prognosis in lung adenocarcinoma patients, and its overexpression can also be used to identify high-risk groups. In conclusion, cell division cycle 20 might serve as a potential biomarker for lung adenocarcinoma patients.
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.|2 Department of Thoracic Surgery, The Affiliated Cancer Hospital, Nanjing Medical University, Nanjing, China.|3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
authors.forename: Run
authors.initials: R
authors.lastname: Shi
authors.affiliation: 4 Department of Cardiothoracic Surgery, Jinling Hospital, Southern Medical University, Nanjing, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Sun
authors.affiliation: 5 The First Clinical College of Nanjing Medical University, Nanjing, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.|2 Department of Thoracic Surgery, The Affiliated Cancer Hospital, Nanjing Medical University, Nanjing, China.|3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.|2 Department of Thoracic Surgery, The Affiliated Cancer Hospital, Nanjing Medical University, Nanjing, China.|3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
authors.forename: Wenjie
authors.initials: W
authors.lastname: Xia
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.
authors.forename: Gaochao
authors.initials: G
authors.lastname: Dong
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.|2 Department of Thoracic Surgery, The Affiliated Cancer Hospital, Nanjing Medical University, Nanjing, China.|3 The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
authors.forename: Anpeng
authors.initials: A
authors.lastname: Wang
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.|2 Department of Thoracic Surgery, The Affiliated Cancer Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Jiang
authors.affiliation: 1 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing, China.|2 Department of Thoracic Surgery, The Affiliated Cancer Hospital, Nanjing Medical University, Nanjing, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Xu
mesh_terms: D000072283:A549 Cells; D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D064199:Cdc20 Proteins / Q000096:biosynthesis* / Q000235:genetics*; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D030541:Databases, Genetic; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics
chemical_list: D064199:Cdc20 Proteins; D012333:RNA, Messenger; C577488:CDC20 protein, human
keywords: Cell division cycle 20; The Cancer Genome Atlas; non-small-cell lung cancer; overexpression; prognosis